228 -5 (79) 2025 - Khusanbaev Kh.Sh., Yusupov A.F. - ASSESSMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE VITREOUS BODY AFTER VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY

ASSESSMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE VITREOUS BODY AFTER VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY

Khusanbaev Kh.Sh. - Republican Specialized Scientific and Practical Center for Eye Microsurgery Tashkent

Yusupov A.F. - Republican Specialized Scientific and Practical Center for Eye Microsurgery Tashkent

Sultanova S.R. - Kimyo International University of Tashkent, Uzbekistan

Resume

This study investigated whether vitrectomy alters the balance of angiogenic in the eyes of patients with proliferative diabetic retinopathy (PDR). Researchers measured the concentrations of VEGF, erythropoietin (EPO), and endostatin in the vitreous of 32 eyes before and several months after vitrectomy. They found that VEGF and EPO significantly decreased after surgery, while endostatin levels remained unchanged. These findings provide biochemical evidence supporting the therapeutic mechanism of vitrectomy in reducing pathological neovascular activity in PDR.

Keywords: diabetic retinopathy, vitrectomy, lazer

First page

1132

Last page

1137

For citation:Khusanbaev Kh.Sh., Yusupov A.F., Sultanova S.R. - ASSESSMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE VITREOUS BODY AFTER VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY//New Day in Medicine 5(79)2025 1132-1137 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-36.
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21(1):143-56.
3. Jackson TL, Donachie PH, Sallam A, et al. Pars plana vitrectomy in proliferative diabetic retinopathy: clinical outcomes and complications. Eye (Lond). 2017;31(6):893-901.
4. Steel DHW, Lotery AJ. Management of proliferative diabetic retinopathy with vitrectomy: indications and outcomes. Eye (Lond). 2021;35(3):753-763.
5. Park J, Cho JH, Park SW, et al. Changes in vitreous cytokines and clinical outcomes after vitrectomy in proliferative diabetic retinopathy. Sci Rep. 2022;12(1):10087.
6. Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on pathogenic molecular pathways. Trends Pharmacol Sci. 2014;35(7):352-358.
7. Zhang L, Hu H, Shi Z, et al. Correlation between vitreous VEGF levels and proliferative diabetic retinopathy severity: A meta-analysis. Ophthalmic Res. 2024;67(2):138-146.
8. Silva PS, Sun JK, Aiello LP. Diabetic retinopathy and diabetic macular edema. Dev Ophthalmol. 2016;55:137-56.
9. Qin L, Zhu T, Wang Y, et al. Vitreous biomarkers of diabetic retinopathy progression and response to treatment. Front Med (Lausanne). 2024;11:789123.
10. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: AAO; 2023.

    file

    download